x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week"s biggest moves in pharma and biotech. Covering drug approvals, pharma industry deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for professionals who need to stay ahead. Hosts voices are AI created.

science life sciences

All Episodes

00:10:11

Daily Roundup | Celcuity Revtorpyk Approved: The...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/07/15

Celcuity's Revtorpyk (gedatolisib) wins FDA approval in HR+/HER2- breast cancer on a 0.24 hazard ratio — and the stock jumped to $111. Plus AstraZeneca's up-to-$1.5B Zegfrovy license from spinoff Dizal, Biogen's diranersen tau data at AAIC, the NextCure–Avere oral IL-23 merger, and Roche scrapping two Ionis Huntington's programs.Visit us at thepharmacloseout.com.

en-us

00:09:56

Daily Roundup | GSK to File Jemperli in Rectal Cancer...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/07/14

GSK will file Jemperli with the FDA for dMMR rectal cancer after a Phase 2 win, extending its PD-1 franchise into curative-intent oncology. Plus Q32 Bio's bempikibart hits its alopecia areata goal, the FDA finalizes psychedelics guidance ahead of a Compass Pathways COMP360 decision, LEQEMBI clears a subcutaneous at-home dose for Eisai and Biogen, Hengrui and Elevar's PD-1 liver cancer combo is rejected a third time, and Biogen's tau drug diranersen takes the spotlight at AAIC.Visit us at

en-us

00:18:36

Week in Review | AstraZeneca's Wainua Stumbles: The...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/07/13

AstraZeneca's Wainua missed in cardiomyopathy — one of three clinical setbacks in five days even as pharma dealmaking stayed red-hot with Vertex's ~$10B Crinetics buy and GSK's biggest oncology bet in a decade. We break down what the Wainua miss means for the ATTR cardiomyopathy race, Bausch + Lomb's BL1107 glaucoma flop, the third Hengrui/Elevar liver-cancer rejection, Corcept's misread insider sale and late-2026 Cushing's catalyst for relacorilant, plus the week ahead: Q32 Bio's bempikibart in

en-us

00:09:19

Daily Roundup | GSK Ends Alector Neuroscience Bet:...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/07/11

GSK walked away from its $2.2 billion Alector alliance, ending its neuroscience re-entry as clinical setbacks piled up. Plus: the FDA resumes releasing rejection letters with fourteen new CRLs, Hengrui and Elevar's PD-1 liver cancer combo is rejected a third time, Sanofi's subcutaneous Sarclisa wins approval, Pfizer/Astellas and Merck expand Padcev-Keytruda in muscle-invasive bladder cancer, Vera Therapeutics scores an IgA nephropathy nod against Otsuka, AstraZeneca and Ionis miss a Phase 3 heart

en-us

00:13:16

Daily Roundup | Wainua Fails Pivotal ATTR-CM Trial;...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/07/10

AstraZeneca and Ionis's Wainua missed its Phase 3 ATTR-CM endpoint — Ionis fell ~20% while BridgeBio surged ~17%. We break down the CARDIO-TTRansform failure and what it means for Alnylam's Amvuttra and BridgeBio's Attruby, plus Roche scrapping tominersen in Huntington's, GSK exiting its Alector pact, Ipsen's Dysport dual Phase 3 migraine wins, Vera Therapeutics' IgA nephropathy approval versus Otsuka, NICE rejecting Amgen's Lumakras, and Sino Biopharm's China deals with AstraZeneca and GSK.Visit us

en-us

00:10:31

Daily Roundup | FDA Halts Drug Rejection Letters —...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/07/09

The FDA quietly paused publishing complete response letters after a citizen petition — reversing the Makary-era transparency push and closing a live window into rival drug failures. Plus: Sino Biopharmaceutical's dual respiratory deals with AstraZeneca ($200M upfront, TQC3721 in COPD) and GSK (Trelegy and Anoro Ellipta China rights), Vera Therapeutics' Trutakna approval in IgA nephropathy, Bristol Myers' Krazati confirmatory failure in colorectal cancer, Kailera's oral GLP-1 Phase 3 obesity data,

en-us

00:14:08

Daily Roundup | Vera's TRUTAKNA Wins FDA Nod: The...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/07/08

Vera Therapeutics wins FDA accelerated approval for TRUTAKNA (atacicept) in IgA nephropathy on a 42% placebo-adjusted proteinuria cut — setting up a head-to-head with Otsuka's VOYXACT. Plus Oberland Capital's up-to-$400M royalty deal for MeiraGTx eye gene therapies, Novartis cuts 322 New Jersey jobs, Bristol Myers' Krazati confirmatory failure in colorectal cancer, Roche's divarasib KRAS win, and Teva's early repigmentation data.Visit us at thepharmacloseout.com.

en-us

00:10:23

Daily Roundup | Vertex Buys Crinetics for $10B in...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/07/07

Vertex pays $10B cash for Crinetics Pharmaceuticals — its largest deal ever — betting on acromegaly drug Palsonify and Phase 3 CAH candidate atumelnant. Also: Novartis acquires ADC platform Myricx Bio for up to $1.5B; HSBC downgrades Pfizer to Hold after sigvotatug vedotin Phase 3 miss; BMS Krazati confirmatory study fails in CRC as Roche divarasib wins KRAS Phase 3; FDA closes H1 2026 with 23 novel approvals; Casgevy label expands to ages 2+; Roche licenses breast cancer asset from Astex.Visit us

en-us

00:09:31

Enbrel Price Cap Blocked: One Ruling That Could...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/07/04

Federal court blocks Colorado's 70% price cap on Enbrel — ruling could shut down state drug pricing laws nationwide. Plus: Casgevy label expansion to age 2 for SCD/TDT sends CRISPR Therapeutics surging 8%. Moderna mFLUSIVA rally hits 70% ahead of August 5 FDA decision. AstraZeneca-CSPC $1.7B kidney deal; Celea raises $180M for IPF; Orca Bio prices Tregzi at $428K.Visit us at www.thepharmcloseout.compharma, biotech, FDA, clinical trials, drug approvals, Enbrel, Amgen, drug pricing, Casgevy, CRISPR

en-us

00:10:20

Roche Divarasib Beats Both KRAS G12C Rivals in Phase...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/07/04

Roche's divarasib beats both KRAS G12C rivals on PFS and OS in head-to-head Phase 3, hitting survival significance at interim. AstraZeneca returns to CSPC in a $1.7B siRNA kidney disease deal; Abivax surges on $920M raise and cleared obefazimod cancer concerns; Ipsen acquires Memo Therapeutics; BridgeBio secures $1B; Scribe Therapeutics files for IPO; FDA CBER gene therapy leadership transition.Visit us at www.thepharmacloseout.comRoche's divarasib beats both KRAS G12C rivals on PFS and OS in

en-us

00:10:04

July 01, 2026| Tregzi Approved — Orca Bio Opens a New...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/07/02

FDA approves Orca Bio's Tregzi — the first precision-engineered cell therapy for allogeneic transplant, sparking IPO speculation. Plus BridgeBio secures $1B from Sixth Street and KKR at a 100%+ conversion premium, Ipsen's $2.55B deal spree continues with Memo Therapeutics,Merck scraps Alzheimer's drug MK-1167 as AlzeCure lands a $2.2B QuantumCell partnership, and FDA warns Sanofi's Genzyme over Altuviiio production. Visit us at www.thepharmacloseout.compharma, biotech, FDA, clinical

en-us

00:10:53

Jun 30, 2026 | NEJM Retracts Tavneos Pivotal Trial;...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/07/01

NEJM retracts Amgen's ADVOCATE study after FDA findsendpoint data for 9 patients re-evaluated post-unblinding. Plus: Ionis faces the Tryngolza sNDA PDUFA in severe hypertriglyceridemia, AbbVie's Epkinly delivers chemo-free PFS in R/R DLBCL, Ipsen acquires Kartos for up to $1.75B,and Roche enters the TED race with Enspryng Priority Review.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout,

en-us

00:14:12

Jun 26, 2026 | FDA Approves Viridian for Thyroid Eye...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/27

FDA breaks Amgen's Tepezza monopoly with Viridian's Lumvoa approval in thyroid eye disease. Plus Merck KGaA's $11.3B Bio-Techne acquisition, Biogen gutting the Apellis pipeline post-$5.6B deal, CHMP moves to revoke Tavneos, and Lilly's orforglipron PDUFA lands Monday.Www.thepharacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Viridian Therapeutics, Lumvoa, veligrotug, thyroid eye disease, Amgen, Tepezza, Merck KGaA,

en-us

00:09:53

Jun 25, 2026 | Ionis Tryngolza FDA Label Expansion...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/26

FDA approves Ionis Tryngolza as first treatment to reduce pancreatitis risk in severe hypertriglyceridemia — a potential blockbuster expansion. Merck KGaA acquires Bio-Techne for $11.3B in largest deal in a decade. SCOTUS limits Bayer Roundup state-level claims; Gilead-Pfizer ADC divergence deepens.pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Ionis, Tryngolza, olezarsen, hypertriglyceridemia, pancreatitis, FDA approval, Merck

en-us

00:13:02

Jun 24, 2026 | FDA Approves Gilead's Trodelvy for...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/25

Gilead's Trodelvy wins front-line triple-negative breast cancer approval — and the stock barely moves. Lilly expands its Abbisko partnership to $1.9B, Novartis pays $105M upfront to Antares for undruggable cancer targets, and three ADC stories in two days force a class-level reckoning.pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Trodelvy, sacituzumab govitecan, Gilead, TNBC, triple-negative breast cancer, FDA approval, Eli

en-us

00:14:00

Jun 23, 2026 | Pfizer Seagen ADC Fails in Lung Cancer...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/24

Pfizer's sigvotatug vedotin disappoints in Phase 3 NSCLC — another blow to the $43B Seagen deal. Plus CMS settles with Incyte on Opzelura classification, Sangamo Therapeutics closes after 30 years, and Moderna's flu vaccine wins unanimous FDA panel support.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Pfizer, Seagen, sigvotatug vedotin, ADC, antibody-drug conjugate, non-small cell lung

en-us

00:10:01

Jun 22, 2026 | AbbVie's $10.9B Apogee Buy Targets...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/23

AbbVie bets $10.9B on Apogee Therapeutics to challenge Dupixent — its biggest deal since Allergan. Plus: the first CAR-T approved for a solid tumor clears in China, Merck's $10.8B Prometheus IBD bet pays off with a Phase 3 win, and HHS clinical trial reforms target China. Visit www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, AbbVie, Apogee Therapeutics, zumilokibart, Dupixent, Regeneron, Sanofi, CARsgen,

en-us

00:10:48

Jun 19, 2026 | US Probes Germany Drug Pricing;...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/20

US government opens formal probe into Germany's drug pricing reforms, escalating transatlantic pharma trade tensions. Kardigan IPO raises $400M and pops 31%. Moderna flu vaccine gets unanimous FDA advisory panel support ahead of Aug 5 PDUFA. Jazz and AbCellera strike $4.1B T cell engager collaboration.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Germany drug pricing, US trade probe,

en-us

00:13:30

Jun 18, 2026 | Moderna mFlusiva Wins Unanimous VRBPAC...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/19

Moderna's mRNA flu vaccine gets unanimous FDA panel backing — PDUFA August 5. NovoCure's TRIDENT trial misses overall survival in glioblastoma; stock drops ~18%. Biogen acquires immunology startup RayThera for up to $1B; Kardigan IPO raises $400M.Visit us at www.thepharmacloseput.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Moderna, mFlusiva, MRNA, VRBPAC, mRNA flu vaccine, NovoCure, NVCR, TRIDENT, glioblastoma, TTFields,

en-us

00:14:18

Jun 17, 2026 | UniQure AMT-130 Surges 70% on FDA...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/18

UniQure surges 70% as FDA reverses course on Huntington's gene therapy AMT-130 filing path. Jazz and AbCellera strike $4.1B T cell engager deal for GI cancers. Novo Nordisk faces $25M ransom demand after hackers claim drug formulations and AI models. Visit www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, UniQure, QURE, AMT-130, Huntington's disease, gene therapy, FDA accelerated approval, Jazz

en-us

121 results

Similar Podcasts

Mothman Podcast

Mothman Podcast

Autobiography of an Electron

Charles R. Gibson

This is a Science Show

Dustin Driver

Get Into Gate: A Stargate Podcast

Get Into Geek

The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

BZ Group